These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 38751483)

  • 1. Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR
    Yuan Y; Zhang S; Wang T; Wang B; Wang S; Shi J; Sun T; Yin Y; Ouyang Q; Li J; Wen Y; Zhang L; Jiang Z
    Transl Breast Cancer Res; 2023; 4():10. PubMed ID: 38751483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China.
    Jiang H; Zhong J; Wang J; Song G; Di L; Shao B; Zhang R; Liu Y; Zhu A; Wang N; Li H
    Cancer Med; 2024 May; 13(10):e7249. PubMed ID: 38770648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer.
    Zhou J; Wu X; Zhang H; Wang X; Yuan Y; Zhang S; Jiang Z; Wang T
    Breast; 2022 Dec; 66():255-261. PubMed ID: 36375386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Gene Panel Associated With Abemaciclib Utility in
    Brett JO; Dubash TD; Johnson GN; Niemierko A; Mariotti V; Kim LSL; Xi J; Pandey A; Dunne S; Nasrazadani A; Lloyd MR; Kambadakone A; Spring LM; Micalizzi DS; Onozato ML; Che D; Nayar U; Brufsky A; Kalinsky K; Ma CX; O'Shaughnessy J; Han HS; Iafrate AJ; Ryan LY; Juric D; Moy B; Ellisen LW; Maheswaran S; Wagle N; Haber DA; Bardia A; Wander SA
    JCO Precis Oncol; 2023 May; 7():e2200532. PubMed ID: 37141550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.
    Damodaran S; O'Sullivan CC; Elkhanany A; Anderson IC; Barve M; Blau S; Cherian MA; Peguero JA; Goetz MP; Plourde PV; Portman DJ; Moore HCF
    Ann Oncol; 2023 Dec; 34(12):1131-1140. PubMed ID: 38072513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers.
    Navarro-Yepes J; Kettner NM; Rao X; Bishop CS; Bui TN; Wingate HF; Singareeka Raghavendra A; Wang Y; Wang J; Sahin AA; Meric-Bernstam F; Hunt KK; Damodaran S; Tripathy D; Keyomarsi K
    Cancer Res; 2023 Oct; 83(19):3264-3283. PubMed ID: 37384539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line Endocrine Therapy of Hormone Receptor-positive/HER2- negative Advanced Breast Cancer: A Systematic Review and Network Meta-analysis.
    Wang T; Shen G; Li J; Huo X; Wang M; Liu Z; Zhao F; Ren D; Zhao J
    Curr Cancer Drug Targets; 2023; 23(9):718-730. PubMed ID: 37026492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapies for HR+/HER2-breast cancer: Systematic review and network meta-analysis.
    Tong F; Lu Y; Ma HF; Shen J
    Heliyon; 2024 Jun; 10(11):e31583. PubMed ID: 38832268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience.
    Wander SA; Han HS; Zangardi ML; Niemierko A; Mariotti V; Kim LSL; Xi J; Pandey A; Dunne S; Nasrazadani A; Kambadakone A; Stein C; Lloyd MR; Yuen M; Spring LM; Juric D; Kuter I; Sanidas I; Moy B; Mulvey T; Vidula N; Dyson NJ; Ellisen LW; Isakoff S; Wagle N; Brufsky A; Kalinsky K; Ma CX; O'Shaughnessy J; Bardia A
    J Natl Compr Canc Netw; 2021 Mar; ():1-8. PubMed ID: 33761455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Navigating next-generation HR
    Neven P; Dullens L; Han S; Deblander A; Van Herck Y; Van Houdt M; Wildiers H
    Transl Breast Cancer Res; 2023; 4():31. PubMed ID: 38751459
    [No Abstract]   [Full Text] [Related]  

  • 11. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Jiang Z; Li W; Hu X; Zhang Q; Sun T; Cui S; Wang S; Ouyang Q; Yin Y; Geng C; Tong Z; Cheng Y; Pan Y; Sun Y; Wang H; Ouyang T; Gu K; Feng J; Wang X; Wang S; Liu T; Gao J; Cristofanilli M; Ning Z; Lu X
    Lancet Oncol; 2019 Jun; 20(6):806-815. PubMed ID: 31036468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2- Metastatic Breast Cancer Treated with Abemaciclib.
    Smyth EN; Beyrer J; Saverno KR; Hadden E; Abedtash H; DeLuca A; Lawrence GW; Rybowski S
    Drugs Real World Outcomes; 2022 Dec; 9(4):681-693. PubMed ID: 36097254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2- advanced breast cancer.
    Zhao Q; Jiang M; Liu J; Zhang M; He M; Zhou S; Wang J; Mo H; Lan B; Yuan P; Zhang P; Ma F; Li Q; Xu B
    Cancer Biol Med; 2024 Sep; 21(10):934-50. PubMed ID: 39267478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
    Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
    Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK4/6 Inhibitors in Advanced HR+/HER2 - Breast Cancer: A Multicenter Real-World Data Analysis.
    Müller C; Kiver V; Solomayer EF; Wagenpfeil G; Neeb C; Blohmer JU; Abramian AV; Maass N; Schütz F; Kolberg-Liedtke C; Ralser DJ; Rambow AC
    Breast Care (Basel); 2023 Feb; 18(1):31-41. PubMed ID: 36876172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
    Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
    BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tucidinostat in patients with advanced hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: real-world insights.
    Suo J; Zhu K; Zhuang C; Zhong X; Bravaccini S; Maltoni R; Bertucci F; Zheng H; Luo T
    Ann Transl Med; 2023 Dec; 11(12):409. PubMed ID: 38213803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2- Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice.
    Ring A; Karuturi M; Smyth EN; Lokhandwala T; Sheffield KM; Willey J; Lunacsek O; Sapunar F; Cui ZL; Coutinho AD; Rybowski S
    Drugs Real World Outcomes; 2023 Dec; 10(4):589-603. PubMed ID: 37775689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
    Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
    Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study.
    Ha MJ; Singareeka Raghavendra A; Kettner NM; Qiao W; Damodaran S; Layman RM; Hunt KK; Shen Y; Tripathy D; Keyomarsi K
    Int J Cancer; 2022 Jun; 150(12):2025-2037. PubMed ID: 35133007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.